Latest Government Incentives News

Bio-Gene Technology Limited has received a $519,500 R&D tax incentive from the Australian government, supporting its development of innovative bio-insecticides targeting insecticide resistance.

Chimeric Therapeutics has received a $4.5 million R&D tax incentive refund from the Australian Government, underscoring its ongoing investment in innovative cancer cell therapies.

Wide Open Agriculture has received a $586,624 tax rebate for its overseas research activities in Germany, supporting the commercialisation of its proprietary lupin protein products.

ClearVue Technologies has secured an A$881k Australian Government R&D rebate and used part of it to retire a A$409k loan, strengthening its financial position as it advances its solar glass technology.

Elixir Energy has secured a specialized rig imported by Shell to drill the pivotal Lorelle-3 appraisal well in Queensland’s Taroom Trough, with operations set to begin in January 2026. This move aims to validate Elixir’s substantial gas resources adjacent to Shell’s acreage.

FleetPartners Group Limited reported a 3.2% revenue increase to $786.2 million for FY2025, despite a 3.3% decline in net profit after tax to $75.3 million. The company completed its Accelerate program, delivering $6 million in annualised cost savings and declared a final unfranked dividend of 13.6 cents per share.

Tungsten Mining NL’s latest scoping study confirms Mt Mulgine as a globally significant critical minerals project with strong financial prospects and strategic positioning amid tightening tungsten supply.

Immutep Limited has received a significant A$4.6 million cash payment from the French government’s R&D tax incentive scheme, supporting its ongoing immunotherapy clinical programs.

Galan Lithium has completed a $20 million placement and secured Argentine government incentives, advancing its Hombre Muerto West lithium project toward first production in early 2026.

Green & Gold Minerals has successfully listed on the ASX, raising $5.7 million to fund drilling at its Chillagoe Gold Project, with initial results expected soon. The company also holds promising critical minerals prospects in Queensland.

Cambium Bio has locked in a significant R&D tax rebate and forged three strategic partnerships, underpinning its Phase 3 clinical trials for its lead ophthalmology biologic. The company’s recent capital raise further strengthens its runway as it prepares for pivotal trial milestones.

Actinogen Medical has received approval for an additional $1.87 million research and development tax rebate, bringing its total FY25 rebate to $7.36 million. This funding underpins ongoing clinical trials of its Alzheimer’s and depression therapy candidate, Xanamem.